Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407900 | 0.89 | KDM4E (0.56) | KDM4EPKMUSP30GPR119STS | |
| SCHEMBL21848120 | 0.89 | KDM4E (0.56) | KDM4EPKMUSP30GPR119STS | |
| SCHEMBL1156326 | 0.89 | KDM4E (0.56) | KDM4EPKMUSP30GPR119STS | |
| SCHEMBL3325048 | 0.86 | ALDH1A1 (0.58) | KDM4EPKMUSP30GPR119MEN1 | |
| SCHEMBL969043 | 0.86 | ALDH1A1 (0.58) | KDM4EPKMUSP30GPR119MEN1 | |
| SCHEMBL969044 | 0.86 | ALDH1A1 (0.58) | KDM4EPKMUSP30GPR119MEN1 | |
| SCHEMBL441012 | 0.85 | KDM4E (0.62) | KDM4EPKMGPR119STSMEN1 | |
| SCHEMBL4192895 | 0.85 | RORC (0.48) | USP30RORCGPR119MEN1KMT2A | |
| SCHEMBL20568872 | 0.85 | ABL1 (0.44) | KDM4EUSP30RORCGPR119STS | |
| SCHEMBL21381625 | 0.85 | HSD11B1 (0.48) | USP30MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530153-A | Preparation method of 1-Boc-3-azetidinone | 上海津力药业股份有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4419520-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118530153-A | Preparation method of 1-Boc-3-azetidinone | 上海津力药业股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-2882718-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014023258-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| WO-2010114907-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | ADRM1, PSMD7, UBQLN2 | KDM4E 2086/4885PKM 2008/4885USP30 46/4885 |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC18A2 | KDM4E 1642/4885PKM 2832/4885USP30 2955/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | KDM4E 3500/4885PKM 1273/4885USP30 1590/4885 |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDM4E 1669/4885PKM 325/4885USP30 4008/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | KDM4E 1446/4885PKM 2279/4885USP30 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.